Related references
Note: Only part of the references are listed.Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma
J. N. Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Hans Skovgaard Poulsen et al.
ACTA ONCOLOGICA (2009)
Vascular permeability, vascular hyperpermeability and angiogenesis
Janice A. Nagy et al.
ANGIOGENESIS (2008)
Neuropilins: structure, function and role in disease
Caroline Pellet-Many et al.
BIOCHEMICAL JOURNAL (2008)
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells
Jian Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability
Albert Lai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
J. F. De Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase II trial of sunitinib in patients with recurrent high-grade glioma
C. Chaskis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS)
N. A. Butowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
T. F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model
Maria Sandstrom et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
Sheikh A. Ali et al.
JOURNAL OF NEUROSURGERY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Sophie de Boueard et al.
NEURO-ONCOLOGY (2007)
Vasculogenic mimicry: Current status and future prospects
Shiwu Zhang et al.
CANCER LETTERS (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway
B. Hu et al.
ONCOGENE (2007)
Tumor growth need not be driven by rare cancer stem cells
Priscilla N. Kelly et al.
SCIENCE (2007)
Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma
Michal Sieniawski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
Dagmar Beier et al.
CANCER RESEARCH (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Antiangiogenic therapy in malignant glioma: Promise and challenge
Sith Sathornsumetee et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth
Qi Pan et al.
CANCER CELL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion
David Zagzag et al.
LABORATORY INVESTIGATION (2006)
Angiogenesis-independent tumor growth mediated by stem-like cancer cells
Per O. Sakariassen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migration
Adriana Bajetto et al.
NEUROCHEMISTRY INTERNATIONAL (2006)
Difference in risk of cerebral aneurysm recurrence after surgical treatment between ruptured and unruptured patients
Motoshi Sawada et al.
NEUROSURGERY (2006)
Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain
Justin G. Santarelli et al.
NEUROSURGERY (2006)
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice
Susan Jones-Bolin et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Biology of vascular endothelial growth factors
Himadri Roy et al.
FEBS LETTERS (2006)
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
Jeongwu Lee et al.
CANCER CELL (2006)
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
LX Sun et al.
CANCER CELL (2006)
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors
DG Duda et al.
BLOOD (2006)
Neuropilins in neoplasms: Expression, regulation, and function
DR Bielenberg et al.
EXPERIMENTAL CELL RESEARCH (2006)
From angiogenesis to neuropathology
DA Greenberg et al.
NATURE (2005)
Does vasculogenic mimicry exist in astrocytoma?
WY Yue et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2005)
Common mechanisms of nerve and blood vessel wiring
P Carmeliet et al.
NATURE (2005)
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
DJ Brat et al.
NEURO-ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2
M Murga et al.
BLOOD (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors
H Broholm et al.
APMIS (2004)
Oncogenes and tumor angiogenesis - The question of vascular 'supply' and vascular 'demand'
J Rak et al.
SEMINARS IN CANCER BIOLOGY (2004)
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
I Garkavtsev et al.
NATURE (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma
R Galli et al.
CANCER RESEARCH (2004)
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option
WPJ Leenders et al.
CLINICAL CANCER RESEARCH (2004)
PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization
RH Goldbrunner et al.
NEUROSURGERY (2004)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model
MR Machein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
The management of brain edema in brain tumors
ECA Kaal et al.
CURRENT OPINION IN ONCOLOGY (2004)
VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?
D Lambrechts et al.
TRENDS IN MOLECULAR MEDICINE (2004)
Cancerous stem cells can arise from pediatric brain tumors
HD Hemmati et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration
L Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy
S Ran et al.
NEOPLASIA (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro
TN Ignatova et al.
GLIA (2002)
VEGF(165) mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF(165)-receptor binding
S Soker et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Vascular-specific growth factors and blood vessel formation
GD Yancopoulos et al.
NATURE (2000)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
Vasculogenic mimicry and tumor angiogenesis
R Folberg et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
